Print

Rosetta Genomics Ltd. (ROSG) Announces that Johns Hopkins University Researchers Demonstrate miRview(TM) squamous Classifies Non-Small Cell Lung Cancer with Extremely High Degree of Accuracy  
1/13/2010 9:38:55 AM

REHOVOT, Israel & PHILADELPHIA--(BUSINESS WIRE)--Rosetta Genomics, Ltd. (NASDAQ: ROSG), a leading developer and provider of microRNA-based molecular diagnostics, announced today that the results of a joint study with the Department of Pathology at Johns Hopkins University School of Medicine were published online yesterday, January 12th, and are set to be published in the January 15, 2010 issue of the American Association for Cancer Research’s journal Clinical Cancer Research. The study, ”Accurate classification of non-small cell lung carcinoma using a novel microRNA-based approach,” shows that Rosetta Genomics’ miRview™ squamous test accurately classified NSCLC samples both from resections, as well as from fine-needle aspirate (FNA) cell blocks. The abstract of the study may be viewed online at the Clinical Cancer Research’s website: http://clincancerres.aacrjournals.org/content/early/2010/01/10/1078-0432.CCR-09-2638.abstract
//-->